The SK Group has been reviewing a proposal to invest some 94.2 billion won for a 10 percent stake in Malaysian-flagged Air Asia.
Industry observers that SK Group is interested in a mere stake acquisition in Air Asia and not into focusing on aviation.
There are also doubts about whether SK would invest in Air Asia since the global aviation industry is going through severe turmoil due to the pandemic.
The proposal was sent to SK Southeast Asia Investment Corp., the group’s investment arm operating in the region, which has been investing mostly in Vietnam.
In 2018, the investment arm acquired a 9.5 percent stake in Vietnam’s Masan Group for 570 billion won. Last year, it bought a 6.1 percent stake Binh Group, Vietnam’s largest private business group, for 1.2 trillion won.


Philips Shares Slide 10% Despite Earnings Beat as Weak Orders Raise Growth Concerns
Russia Charges Telegram Founder Pavel Durov With Facilitating Terrorism, Seeks International Arrest
Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer
Rio Tinto Stock Jumps as Strong Earnings, Higher Dividend and AI Metal Demand Boost Outlook
Samsung Q2 Profit Surges on AI Memory Chip Demand, Forecasts Strong Second Half
Standard Chartered Beats Profit Forecasts as First-Half Earnings Rise 9%
Barclays Q2 Profit Beats Forecasts as Investment Banking Strength Offsets Higher Costs
Arm Holdings Q1 Earnings Beat Estimates, Strong Q2 Outlook Fails to Lift ARM Stock
OpenAI Revenue Surges After GPT-5.6 Launch as IPO Expectations Grow
Exosens H1 Profit Beats Forecasts as Defense Demand Drives Growth
Stellantis Sells Free2move Car-Sharing Business to Mutares to Strengthen Core Auto Strategy
Microsoft Stock Jumps as Azure Growth, AI Revenue Beat Expectations
Chipotle Q2 Earnings Beat Expectations as Sales Growth Drives Higher 2026 Outlook
Air Liquide Q2 Sales Growth Tops Forecast as Electronics Business Drives Strong Performance
Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality
Meta CEO Zuckerberg Opposes U.S. Ban on Chinese AI Models, Warns Against Overregulation
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 



